CHESHIRE, Connecticut, December 10 /PRNewswire/ --

- Study Shows that Long-Term Soliris Therapy Continued to Be Associated with Reductions in Thrombosis and Improvements in Fatigue, Quality of Life, and Anemia in PNH Patients

- Data Presented at the American Society of Hematology (ASH) Annual Meeting

Posters: 897-III & 891-III

BRISTOL, England, December 10 /PRNewswire/ --

- The Creators of 'PaRappa the Rapper' Return With Music-Based Video Game

Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of video games for the mass market, today announced a partnership with legendary multimedia musician and game designer, Masaya Matsuura, and famed New York artist Rodney Alan Greenblat, to develop and publish an original music-based video game scheduled for release in late 2008. Creators of the highly acclaimed, best-selling PaRappa the Rapper series, Matsuura and Greenblat will bring their engaging gameplay and distinctive art style to the Wii(TM) home video game system for the first time.

HALIFAX, Canada, December 10 /PRNewswire/ -- ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

CALGARY, Canada, December 10 /PRNewswire/ --

- New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic

Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

AMSTERDAM, December 10 /PRNewswire/ -- BMEYE(TM) announced today that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) to market Nexfin(TM), their newly developed line of safe, precise and easy to use hemodynamic monitors. The Nexfin(TM) monitors provide precise and easy to use continuous non-invasive blood pressure and cardiac output monitoring. BMEYE(TM) received CE market approval earlier this year.

MILPITAS, California, December 10 /PRNewswire/ --